Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 407

1.

[Working Conditions and Quality of Specialized Training in Respiratory Medicine in Germany - Status quo, Challenges and Perspectives].

Bahmer T, Wälscher J, Fisser C, Kreuter M, Karg O, Böing S, Koczulla R, Raspe M.

Pneumologie. 2019 Oct;73(10):578-581. doi: 10.1055/a-1010-2863. Epub 2019 Oct 17. German. No abstract available.

PMID:
31622996
2.

Direct interplay between stereochemistry and conformational preferences in aminoacylated oligoribonucleotides.

Polyansky AA, Kreuter M, Sutherland JD, Zagrovic B.

Nucleic Acids Res. 2019 Oct 15. pii: gkz902. doi: 10.1093/nar/gkz902. [Epub ahead of print]

PMID:
31612955
3.

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.

Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V.

Lancet Respir Med. 2019 Sep 27. pii: S2213-2600(19)30341-8. doi: 10.1016/S2213-2600(19)30341-8. [Epub ahead of print]

PMID:
31578169
4.

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design.

Santermans E, Ford P, Kreuter M, Verbruggen N, Meyvisch P, Wuyts WA, Brown KK, Lederer DJ, Byrne AJ, Molyneaux PL, Sivananthan A, Moor CC, Maher TM, Wijsenbeek M.

Adv Ther. 2019 Sep 29. doi: 10.1007/s12325-019-01093-3. [Epub ahead of print]

PMID:
31565781
5.

Concomitant Medications and Clinical Outcomes in Idiopathic Pulmonary Fibrosis.

Kreuter M, Lederer DJ, Cottin V, Kahn N, Ley B, Vancheri C, Weycker D, Atwood M, Kirchgaessler KU, Ryerson CJ.

Eur Respir J. 2019 Sep 19. pii: 1901188. doi: 10.1183/13993003.01188-2019. [Epub ahead of print] No abstract available.

PMID:
31537696
6.

[New ways in the treatment of SSc-ILD: what makes sense?]

Kreuter M, Hoffmann-Vold AM.

Z Rheumatol. 2019 Sep 4. doi: 10.1007/s00393-019-00704-2. [Epub ahead of print] German. No abstract available.

PMID:
31485729
7.

The therapy of idiopathic pulmonary fibrosis: what is next?

Somogyi V, Chaudhuri N, Torrisi SE, Kahn N, Müller V, Kreuter M.

Eur Respir Rev. 2019 Sep 4;28(153). pii: 190021. doi: 10.1183/16000617.0021-2019. Print 2019 Sep 30. Review. Erratum in: Eur Respir Rev. 2019 Sep 25;28(153):.

8.

Antwort.

Kreuter M.

Pneumologie. 2019 Aug;73(8):462. doi: 10.1055/a-0970-6200. Epub 2019 Aug 14. German. No abstract available.

PMID:
31412397
9.

Angiotensin Receptor Blockers and Subclinical Interstitial Lung Disease: The MESA Study.

Gannon WD, Anderson MR, Podolanczuk AJ, Kawut SM, Michos ED, Cottin V, Kreuter M, Raghu G, Barr RG, Lederer DJ.

Ann Am Thorac Soc. 2019 Jul 31. doi: 10.1513/AnnalsATS.201903-198RL. [Epub ahead of print] No abstract available.

PMID:
31365837
10.

Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.

Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD, Denton CP, Mounir B, Zouad-Lejour L, Quaresma M, Cottin V.

Curr Med Res Opin. 2019 Nov;35(11):2015-2024. doi: 10.1080/03007995.2019.1647040. Epub 2019 Aug 2.

PMID:
31328965
11.

Bleeding risk of transbronchial cryobiopsy compared to transbronchial forceps biopsy in interstitial lung disease - a prospective, randomized, multicentre cross-over trial.

Hetzel J, Eberhardt R, Petermann C, Gesierich W, Darwiche K, Hagmeyer L, Muche R, Kreuter M, Lewis R, Ehab A, Boeckeler M, Haentschel M.

Respir Res. 2019 Jul 5;20(1):140. doi: 10.1186/s12931-019-1091-1.

12.

Diagnostic Likelihood Thresholds that Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis.

Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU.

Am J Respir Crit Care Med. 2019 Jun 26. doi: 10.1164/rccm.201903-0493OC. [Epub ahead of print]

13.

Where are the gaps in education in the field of rare lung disease? Perspectives from the ERN-LUNG educational programme survey.

Powell P, Kreuter M, Wijsenbeek-Lourens M.

Breathe (Sheff). 2019 Jun;15(2):102-103. doi: 10.1183/20734735.0120-2019.

14.

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).

Maher TM, Kreuter M, Lederer DJ, Brown KK, Wuyts W, Verbruggen N, Stutvoet S, Fieuw A, Ford P, Abi-Saab W, Wijsenbeek M.

BMJ Open Respir Res. 2019 May 21;6(1):e000422. doi: 10.1136/bmjresp-2019-000422. eCollection 2019.

15.

Steps Toward Scalability: Illustrations From a Smoke-Free Homes Program.

Kegler MC, Haardörfer R, Melanson T, Allen L, Bundy LT, Kreuter MW, Williams RS, Hovell MF, Mullen PD.

Health Educ Behav. 2019 Oct;46(5):773-781. doi: 10.1177/1090198119848767. Epub 2019 Jun 5.

PMID:
31165637
16.

Digital Lung Auscultation: Will Early Diagnosis of Fibrotic Interstitial Lung Disease Become a Reality?

Richeldi L, Cottin V, Würtemberger G, Kreuter M, Calvello M, Sgalla G.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):261-263. doi: 10.1164/rccm.201902-0306LE. No abstract available.

PMID:
31150267
17.

Economic burden of incident interstitial lung disease (ILD) and the impact of comorbidity on costs of care.

Frank AL, Kreuter M, Schwarzkopf L.

Respir Med. 2019 Jun;152:25-31. doi: 10.1016/j.rmed.2019.04.009. Epub 2019 Apr 22.

PMID:
31128606
18.

The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis.

Cottin V, Annesi-Maesano I, Günther A, Galvin L, Kreuter M, Powell P, Prasse A, Reynolds G, Richeldi L, Spagnolo P, Valenzuela C, Wijsenbeek M, Wuyts WA, Crestani B; Ariane-IPF Clinical Research Collaboration consortium.

Eur Respir J. 2019 May 23;53(5). pii: 1900539. doi: 10.1183/13993003.00539-2019. Print 2019 May. No abstract available.

PMID:
31123022
19.

Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.

Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Moran D, Santin-Janin H, Aubin F, Mulder GJ, Gupta R, Richeldi L.

Lancet Respir Med. 2019 Aug;7(8):657-664. doi: 10.1016/S2213-2600(19)30172-9. Epub 2019 May 20.

PMID:
31122893
20.

Reply to: Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity!

Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C.

Eur Respir J. 2019 May 9;53(5). pii: 1900615. doi: 10.1183/13993003.00615-2019. Print 2019 May. No abstract available.

PMID:
31072878
21.

Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis.

Kreuter M, Lederer DJ, Molina-Molina M, Noth I, Valenzuela C, Frankenstein L, Weycker D, Atwood M, Kirchgaessler KU, Cottin V.

Chest. 2019 Oct;156(4):706-714. doi: 10.1016/j.chest.2019.04.015. Epub 2019 Apr 29.

22.

Effects of an Oil-Free Hydroethanolic Pumpkin Seed Extract on Symptom Frequency and Severity in Men with Benign Prostatic Hyperplasia: A Pilot Study in Humans.

Leibbrand M, Siefer S, Schön C, Perrinjaquet-Moccetti T, Kompek A, Csernich A, Bucar F, Kreuter MH.

J Med Food. 2019 Jun;22(6):551-559. doi: 10.1089/jmf.2018.0106. Epub 2019 Apr 24.

23.

Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials.

Kreuter M, Koegler H, Trampisch M, Geier S, Richeldi L.

Respir Res. 2019 Apr 11;20(1):71. doi: 10.1186/s12931-019-1037-7.

24.

Can monocytes predict prognosis of idiopathic pulmonary fibrosis?

Kreuter M, Maher TM.

Lancet Respir Med. 2019 Jun;7(6):467-469. doi: 10.1016/S2213-2600(19)30050-5. Epub 2019 Mar 29. No abstract available.

25.

Disseminated Mycosis by Arthrocladium fulminans Jeopardizing a Patient with GATA2 Deficiency.

Egenlauf B, Schuhmann M, Giese T, Junghanss T, Stojkovic M, Tintelnot K, de Hoog S, Greil J, Richter E, Vehresschild M, Heussel CP, Herth FJF, Kreuter M.

Respiration. 2019;97(5):472-475. doi: 10.1159/000493429. Epub 2019 Mar 29.

PMID:
30928982
26.

Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial Pneumonia.

Lyu Y, Boerner E, Theegarten D, Guzman J, Kreuter M, Costabel U, Bonella F.

Respiration. 2019;98(1):29-37. doi: 10.1159/000496483. Epub 2019 Mar 29.

PMID:
30928980
27.

Improving Adherence to Colorectal Cancer Screening: A Randomized Intervention to Compare Screener vs. Survivor Narratives.

McQueen A, Caburnay C, Kreuter M, Sefko J.

J Health Commun. 2019;24(2):141-155. doi: 10.1080/10810730.2019.1587109. Epub 2019 Mar 29.

PMID:
30924402
28.

Specialized tobacco quitline and basic needs navigation interventions to increase cessation among low income smokers: Study protocol for a randomized controlled trial.

McQueen A, Roberts C, Garg R, Caburnay C, Fu Q, Gordon J, Bush T, Pokojski R, Thompson T, Kreuter M.

Contemp Clin Trials. 2019 May;80:40-47. doi: 10.1016/j.cct.2019.03.009. Epub 2019 Mar 20.

PMID:
30904596
29.

The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry.

Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, Wirtz H, Koschel D, Andreas S, Claussen M, Grohé C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Gläser S, Kahn N, Welte T, Neurohr C, Schwaiblmair M, Held M, Bahmer T, Oqueka T, Frankenberger M, Behr J.

Respir Res. 2019 Mar 15;20(1):59. doi: 10.1186/s12931-019-1020-3.

30.

[Acute hemoptysis and crazy-paving pattern].

Wagner WL, Rothermel A, Optazaite DE, Schneider D, Kreuter M, Kauczor HU, Heußel CP.

Med Klin Intensivmed Notfmed. 2019 Sep;114(6):558-560. doi: 10.1007/s00063-019-0554-y. Epub 2019 Feb 25. German. No abstract available.

PMID:
30805661
31.

Research highlights from the 2018 ERS International Congress: interstitial lung diseases.

Alfaro TM, Moor CC, Alfieri V, Jeny F, Kreuter M, Wijsenbeek MS, Renzoni EA, Bargagli E, Nunes H, Spagnolo P, Bonella F, Molina-Molina M, Antoniou K, Poletti V.

ERJ Open Res. 2019 Feb 18;5(1). pii: 00215-2018. doi: 10.1183/23120541.00215-2018. eCollection 2019 Feb. Review.

32.

Corrigendum to "Perceived social support in African American breast cancer patients: Predictors and effects" [Soc. Sci. Med. 192 (2017) 134-142].

Thompson T, Pérez M, Kreuter M, Margenthaler J, Colditz G, Jeffe DB.

Soc Sci Med. 2019 Feb;223:117-120. doi: 10.1016/j.socscimed.2019.01.030. Epub 2019 Feb 1. No abstract available.

33.

Social Needs and Health-Related Outcomes Among Medicaid Beneficiaries.

Thompson T, McQueen A, Croston M, Luke A, Caito N, Quinn K, Funaro J, Kreuter MW.

Health Educ Behav. 2019 Jun;46(3):436-444. doi: 10.1177/1090198118822724. Epub 2019 Jan 17.

PMID:
30654655
34.

Effect of a chamomile extract in protecting against radiation-induced intestinal mucositis.

Khayyal MT, Kreuter MH, Kemmler M, Altmann P, Abdel-Naby DH, El-Ghazaly MA.

Phytother Res. 2019 Mar;33(3):728-736. doi: 10.1002/ptr.6263. Epub 2019 Jan 10.

PMID:
30632234
35.

The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study.

Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C.

Eur Respir J. 2019 Mar 7;53(3). pii: 1801587. doi: 10.1183/13993003.01587-2018. Print 2019 Mar.

PMID:
30578385
36.

Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases.

Holtze C, Flaherty K, Kreuter M, Luppi F, Moua T, Vancheri C, Scholand MB.

Eur Respir Rev. 2018 Dec 21;27(150). pii: 180078. doi: 10.1183/16000617.0078-2018. Print 2018 Dec 31. Review.

37.

Transbronchial Cryobiopsies for Diagnosing Interstitial Lung Disease: Real-Life Experience from a Tertiary Referral Center for Interstitial Lung Disease.

Wälscher J, Groß B, Eberhardt R, Heussel CP, Eichinger M, Warth A, Lasitschka F, Herth FJF, Kreuter M.

Respiration. 2019;97(4):348-354. doi: 10.1159/000493428. Epub 2018 Dec 14.

PMID:
30554201
38.

Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events.

Bendstrup E, Wuyts W, Alfaro T, Chaudhuri N, Cornelissen R, Kreuter M, Melgaard Nielsen K, Münster AB, Myllärniemi M, Ravaglia C, Vanuytsel T, Wijsenbeek M.

Respiration. 2019;97(2):173-184. doi: 10.1159/000495046. Epub 2018 Dec 13. Review.

PMID:
30544129
39.

[Sirolimus for LAM - A New MILEStone Reached?]

Kreuter M, Wirtz H.

Pneumologie. 2019 Jan;73(1):22-23. doi: 10.1055/a-0802-3633. Epub 2018 Dec 12. German. No abstract available.

PMID:
30541159
40.

Disseminating a Smoke Free Homes program to low SES households in the US through 2-1-1: Results of a national impact evaluation.

Bundy LT, Haardörfer R, Kegler MC, Owolabi S, Berg CJ, Escoffery C, Thompson T, Mullen PD, Williams R, Hovell M, Kahl T, Harvey D, Price A, House D, Booker BW, Kreuter MW.

Nicotine Tob Res. 2018 Dec 5. doi: 10.1093/ntr/nty256. [Epub ahead of print]

PMID:
30517679
41.

Impact of FDG-PET on the Detection of Patients with Lung Cancer at High Risk for ILD.

Flechsig P, Hural O, Kreuter M, Eichhorn M, HEUßEL G, Sachpekidis C, Kauczor HU, Haberkorn U, Heussel CP, Eichinger M.

In Vivo. 2018 Nov-Dec;32(6):1457-1462. doi: 10.21873/invivo.11399.

42.

Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies.

Wang Z, Bonella F, Li W, Boerner EB, Guo Q, Kong X, Zhang X, Costabel U, Kreuter M.

Respiration. 2018;96(6):571-587. doi: 10.1159/000492336. Epub 2018 Oct 11. Review.

PMID:
30308515
43.

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial.

Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Cottin V.

BMJ Open Respir Res. 2018 Sep 4;5(1):e000289. doi: 10.1136/bmjresp-2018-000289. eCollection 2018.

44.

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.

Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, Song JW, Stansen W, Quaresma M, Stowasser S, Kreuter M.

Lancet Respir Med. 2019 Jan;7(1):60-68. doi: 10.1016/S2213-2600(18)30339-4. Epub 2018 Sep 14.

PMID:
30224318
45.

Should Patients With Interstitial Lung Disease Be Seen by Experts?

Cottin V, Castillo D, Poletti V, Kreuter M, Corte TJ, Spagnolo P.

Chest. 2018 Sep;154(3):713-714. doi: 10.1016/j.chest.2018.05.044. No abstract available.

PMID:
30195349
46.

Interstitial lung diseases: course report.

Kreuter M, Calaras D.

Breathe (Sheff). 2018 Sep;14(3):184-185. doi: 10.1183/20734735.019718.

47.

Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis.

Kwapiszewska G, Gungl A, Wilhelm J, Marsh LM, Thekkekara Puthenparampil H, Sinn K, Didiasova M, Klepetko W, Kosanovic D, Schermuly RT, Wujak L, Weiss B, Schaefer L, Schneider M, Kreuter M, Olschewski A, Seeger W, Olschewski H, Wygrecka M.

Eur Respir J. 2018 Nov 22;52(5). pii: 1800564. doi: 10.1183/13993003.00564-2018. Print 2018 Nov.

48.

Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views.

Maher TM, Swigris JJ, Kreuter M, Wijsenbeek M, Cassidy N, Ireland L, Axmann J, Nathan SD.

Respiration. 2018;96(6):514-524. doi: 10.1159/000490667. Epub 2018 Aug 16.

49.

Moderators of Establishing a Smoke-Free Home: Pooled Data from Three Randomized Controlled Trials of a Brief Intervention.

Kegler MC, Haardörfer R, Bundy LT, Escoffery C, Williams RS, Hovell M, Kreuter M, Mullen PD.

J Community Health. 2019 Feb;44(1):121-126. doi: 10.1007/s10900-018-0561-6.

PMID:
30101386
50.

A Face-Aging Smoking Prevention/Cessation Intervention for Nursery School Students in Germany: An Appearance-Focused Interventional Study.

Brinker TJ, Alfitian J, Seeger W, Groneberg DA, von Kalle C, Enk AH, Herth FJF, Kreuter M, Bauer CM, Gatzka M, Suhre JL.

Int J Environ Res Public Health. 2018 Aug 4;15(8). pii: E1656. doi: 10.3390/ijerph15081656.

Supplemental Content

Loading ...
Support Center